{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:51:08Z","timestamp":1778529068408,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.msard.2024.105600","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T06:04:35Z","timestamp":1711951475000},"page":"105600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"86","author":[{"given":"Lei","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dantao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujuan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6392-5664","authenticated-orcid":false,"given":"Weihe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105600_bib0001","doi-asserted-by":"crossref","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term Effectiveness and Safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105600_bib0002","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00277-016-2731-x","article-title":"Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma\/leukemia","volume":"95","author":"Burkhardt","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.msard.2024.105600_bib0003","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1080\/10428190903161109","article-title":"FCGR3A polymorphism story: a new piece of the puzzle","volume":"50","author":"Cartron","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.msard.2024.105600_bib0004","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neurol.2017.11.005","article-title":"Recommendations for the use of rituximab in neuromyelitis optica spectrum disorders","volume":"174","author":"Ciron","year":"2018","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.msard.2024.105600_bib0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00277-011-1369-y","article-title":"Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy","volume":"91","author":"Cornec","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.msard.2024.105600_bib0006","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","article-title":"Neuromyelitis optica spectrum disorders: still evolving and broadening","volume":"32","author":"Fujihara","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2024.105600_bib0007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12883-018-1056-x","article-title":"Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study","volume":"18","author":"Jiao","year":"2018","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2024.105600_bib0008","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2024.105600_bib0009","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"FcgRIIIa-158 V\/F polymorphism influences the binding of IgG by natural killer cell FcgRIIIa, independently of the FcgRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.msard.2024.105600_bib0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2024.105600_bib0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","article-title":"Anti-rituximab antibody in patients with NMOSDs treated with low dose rituximab","volume":"316","author":"Li","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2024.105600_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101933","article-title":"A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders","volume":"40","author":"Lu","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105600_bib0013","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jcph.1341","article-title":"FCGR2A\/FCGR3A gene polymorphisms and clinical variables as predictors of response to tocilizumab and rituximab in patients with rheumatoid arthritis","volume":"59","author":"Morales","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2024.105600_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101430","article-title":"Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders","volume":"36","author":"Novi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105600_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200124","article-title":"International delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2024.105600_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104343","article-title":"Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity","volume":"86","author":"Robinson","year":"2022","journal-title":"EBioMedicine"},{"issue":"3&4","key":"10.1016\/j.msard.2024.105600_bib0017","first-page":"335","article-title":"Development of anti-rituximab antibodies in rituximab-treated patients: related parameters & consequences","volume":"155","author":"Saffari","year":"2022","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.msard.2024.105600_bib0018","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105600_bib0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105600_bib0020","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105600_bib0021","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","article-title":"Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study","volume":"117","author":"Zhang","year":"2017","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2024.105600_bib0022","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-019-09685-3","article-title":"Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population","volume":"267","author":"Zhang","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105600_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1047992","article-title":"Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: a case report","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2024.105600_bib0024","article-title":"Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T23:21:26Z","timestamp":1715037686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824001792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":24,"alternative-id":["S2211034824001792"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105600","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105600","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105600"}}